Commentary: Preoperative gefitinib for stage II-III non-small cell lung cancer with EGFR mutation: A stich in time, or delay from stiches?

J Thorac Cardiovasc Surg. 2021 Feb;161(2):444-446. doi: 10.1016/j.jtcvs.2020.04.028. Epub 2020 Apr 18.

Authors

Christopher G Azzoli¹, Thomas Ng²

Affiliations

¹ Divison of Hematology/Oncology, Warren Alpert Medical School of Brown University, Providence, RI.
² Division of Thoracic Surgery, University of Tennessee Health Science Center College of Medicine, Memphis, Tenn. Electronic address: tng4@uthsc.edu.

PMID: 32444180
DOI: 10.1016/j.jtcvs.2020.04.028

No abstract available

Publication types

Editorial
Comment

MeSH terms

Carcinoma, Non-Small-Cell Lung* / drug therapy
Carcinoma, Non-Small-Cell Lung* / genetics
ErbB Receptors / genetics
Gefitinib / therapeutic use
Humans
Lung Neoplasms* / drug therapy
Lung Neoplasms* / genetics
Mutation
Neoadjuvant Therapy

Substances

EGFR protein, human
ErbB Receptors
Gefitinib